Record Information |
---|
Version | 5.0 |
---|
Status | Detected but not Quantified |
---|
Creation Date | 2021-09-11 10:33:13 UTC |
---|
Update Date | 2021-09-26 23:05:19 UTC |
---|
HMDB ID | HMDB0252624 |
---|
Secondary Accession Numbers | None |
---|
Metabolite Identification |
---|
Common Name | (E)-(4R,9As)-7-[3-Methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-4-(3,4,5-trifluorophenyl)hexahydropyrido[2,1-c][1,4]oxazin-6-one |
---|
Description | 7-{[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]methylidene}-4-(3,4,5-trifluorophenyl)-octahydropyrido[2,1-c][1,4]oxazin-6-one belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety. Based on a literature review very few articles have been published on 7-{[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]methylidene}-4-(3,4,5-trifluorophenyl)-octahydropyrido[2,1-c][1,4]oxazin-6-one. This compound has been identified in human blood as reported by (PMID: 31557052 ). (e)-(4r,9as)-7-[3-methoxy-4-(4-methyl-1h-imidazol-1-yl)benzylidene]-4-(3,4,5-trifluorophenyl)hexahydropyrido[2,1-c][1,4]oxazin-6-one is not a naturally occurring metabolite and is only found in those individuals exposed to this compound or its derivatives. Technically (E)-(4R,9As)-7-[3-Methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-4-(3,4,5-trifluorophenyl)hexahydropyrido[2,1-c][1,4]oxazin-6-one is part of the human exposome. The exposome can be defined as the collection of all the exposures of an individual in a lifetime and how those exposures relate to health. An individual's exposure begins before birth and includes insults from environmental and occupational sources. |
---|
Structure | COC1=C(C=CC(C=C2CCC3COCC(N3C2=O)C2=CC(F)=C(F)C(F)=C2)=C1)N1C=NC(C)=C1 InChI=1S/C26H24F3N3O3/c1-15-11-31(14-30-15)22-6-3-16(8-24(22)34-2)7-17-4-5-19-12-35-13-23(32(19)26(17)33)18-9-20(27)25(29)21(28)10-18/h3,6-11,14,19,23H,4-5,12-13H2,1-2H3 |
---|
Synonyms | Not Available |
---|
Chemical Formula | C26H24F3N3O3 |
---|
Average Molecular Weight | 483.491 |
---|
Monoisotopic Molecular Weight | 483.176976134 |
---|
IUPAC Name | 7-{[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]methylidene}-4-(3,4,5-trifluorophenyl)-octahydropyrido[2,1-c][1,4]oxazin-6-one |
---|
Traditional Name | 7-{[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]methylidene}-4-(3,4,5-trifluorophenyl)-hexahydropyrido[2,1-c][1,4]oxazin-6-one |
---|
CAS Registry Number | Not Available |
---|
SMILES | COC1=C(C=CC(C=C2CCC3COCC(N3C2=O)C2=CC(F)=C(F)C(F)=C2)=C1)N1C=NC(C)=C1 |
---|
InChI Identifier | InChI=1S/C26H24F3N3O3/c1-15-11-31(14-30-15)22-6-3-16(8-24(22)34-2)7-17-4-5-19-12-35-13-23(32(19)26(17)33)18-9-20(27)25(29)21(28)10-18/h3,6-11,14,19,23H,4-5,12-13H2,1-2H3 |
---|
InChI Key | VHNYOQKVZQVBLC-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety. |
---|
Kingdom | Organic compounds |
---|
Super Class | Lipids and lipid-like molecules |
---|
Class | Steroids and steroid derivatives |
---|
Sub Class | Pregnane steroids |
---|
Direct Parent | Gluco/mineralocorticoids, progestogins and derivatives |
---|
Alternative Parents | |
---|
Substituents | - Progestogin-skeleton
- 20-oxosteroid
- Oxosteroid
- Hydroxysteroid
- 3-hydroxysteroid
- Tertiary alcohol
- Cyclic alcohol
- Ketone
- Organic oxygen compound
- Organic oxide
- Hydrocarbon derivative
- Organooxygen compound
- Carbonyl group
- Alcohol
- Aliphatic homopolycyclic compound
|
---|
Molecular Framework | Aliphatic homopolycyclic compounds |
---|
External Descriptors | Not Available |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Not Available |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedMetabolite | SMILES | Kovats RI Value | Column Type | Reference |
---|
(E)-(4R,9As)-7-[3-Methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-4-(3,4,5-trifluorophenyl)hexahydropyrido[2,1-c][1,4]oxazin-6-one | COC1=C(C=CC(C=C2CCC3COCC(N3C2=O)C2=CC(F)=C(F)C(F)=C2)=C1)N1C=NC(C)=C1 | 4338.2 | Standard polar | 33892256 | (E)-(4R,9As)-7-[3-Methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-4-(3,4,5-trifluorophenyl)hexahydropyrido[2,1-c][1,4]oxazin-6-one | COC1=C(C=CC(C=C2CCC3COCC(N3C2=O)C2=CC(F)=C(F)C(F)=C2)=C1)N1C=NC(C)=C1 | 3343.9 | Standard non polar | 33892256 | (E)-(4R,9As)-7-[3-Methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-4-(3,4,5-trifluorophenyl)hexahydropyrido[2,1-c][1,4]oxazin-6-one | COC1=C(C=CC(C=C2CCC3COCC(N3C2=O)C2=CC(F)=C(F)C(F)=C2)=C1)N1C=NC(C)=C1 | 3903.2 | Semi standard non polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - (E)-(4R,9As)-7-[3-Methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-4-(3,4,5-trifluorophenyl)hexahydropyrido[2,1-c][1,4]oxazin-6-one GC-MS (Non-derivatized) - 70eV, Positive | splash10-0pbc-0630900000-238f1244a098baa96029 | 2021-09-24 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - (E)-(4R,9As)-7-[3-Methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-4-(3,4,5-trifluorophenyl)hexahydropyrido[2,1-c][1,4]oxazin-6-one GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - (E)-(4R,9As)-7-[3-Methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-4-(3,4,5-trifluorophenyl)hexahydropyrido[2,1-c][1,4]oxazin-6-one 10V, Positive-QTOF | splash10-001i-0000900000-8c6e169f6c7d4e74718d | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - (E)-(4R,9As)-7-[3-Methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-4-(3,4,5-trifluorophenyl)hexahydropyrido[2,1-c][1,4]oxazin-6-one 20V, Positive-QTOF | splash10-001i-0000900000-b95646e9e32d5fe89519 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - (E)-(4R,9As)-7-[3-Methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-4-(3,4,5-trifluorophenyl)hexahydropyrido[2,1-c][1,4]oxazin-6-one 40V, Positive-QTOF | splash10-053r-5161900000-b69ede5401cc87060d26 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - (E)-(4R,9As)-7-[3-Methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-4-(3,4,5-trifluorophenyl)hexahydropyrido[2,1-c][1,4]oxazin-6-one 10V, Negative-QTOF | splash10-001i-1000900000-d5df1979f39848aadb96 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - (E)-(4R,9As)-7-[3-Methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-4-(3,4,5-trifluorophenyl)hexahydropyrido[2,1-c][1,4]oxazin-6-one 20V, Negative-QTOF | splash10-001i-0000900000-6b5d388c517f927144a0 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - (E)-(4R,9As)-7-[3-Methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]-4-(3,4,5-trifluorophenyl)hexahydropyrido[2,1-c][1,4]oxazin-6-one 40V, Negative-QTOF | splash10-001i-1300900000-0cef13708193debe8b11 | 2021-10-12 | Wishart Lab | View Spectrum |
|
---|